JCO

FAA Selects D-Fend Solutions' EnforceAir for UAS Detection and Mitigation Testing and Evaluation Program Aimed at Enhancing Aviation Safety

Retrieved on: 
Tuesday, August 29, 2023
Federal Aviation Administration, UAS, United States Department of Defense, DHS, Airport, JCO, FAA, Atlantic City International Airport, C-UAS, FAA Reauthorization Act of 2018, KACY, Mitigation, Justice minister, Risk management

RA'ANANA, Israel and MCLEAN, Va., Aug. 29, 2023 /PRNewswire/ -- D-Fend Solutions, the leader in radio frequency (RF), cyber-based, non-kinetic, non-jamming, counter-drone detection and takeover technology, has been selected for participation in the Federal Aviation Administration (FAA)'s Airport UAS Detection and Mitigation Research Program, under Section 383 of the FAA Reauthorization Act of 2018.  D-Fend Solutions' core C-UAS system, EnforceAir, will undergo initial testing at Atlantic City International Airport (KACY) and potential further evaluation at other airport environments.

Key Points: 
  • D-Fend Solutions' core C-UAS system, EnforceAir , will undergo initial testing at Atlantic City International Airport (KACY) and potential further evaluation at other airport environments.
  • D-Fend Solutions' EnforceAir is the first RF-cyber based advanced protocol full takeover UAS detection and mitigation system selected for the program.
  • The system provides 360 degree and long-range directional protection and coverage to protect airport facilities and takeoff and landing airspace corridors.
  • "We are gratified to be selected for this prestigious and selective program, and we commend the FAA for prioritizing requirements for the safest forms of non-disruptive mitigation technology that allow for airport operational continuity."

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Retrieved on: 
Tuesday, August 22, 2023
Health, Genetics, Pharmaceutical, Clinical Trials, Oncology, Duke University, Prostate-specific antigen, Genomics, HRD, Neoplasm, ADT, Prostate, Prostatectomy, JCO, PFS, NCCN, Radiation, SCM, HIV disease progression rates, STREAM, Patient, PTEN, Manuscript, Risk, GRID, Urology, RT, Recurrence, Safety, PSA, Disease, Prostate cancer, Medical imaging, Research, Medicine

(Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting patient response to treatment for recurrent prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting patient response to treatment for recurrent prostate cancer.
  • The findings, from the Phase 2 STREAM study, suggest the potential to use transcriptomic signatures to identify patients in this setting who may benefit from more intensive salvage therapy as well as those who may need alternative care such as chemotherapy.
  • A previous publication demonstrated that 51% of men remained free of disease at three years following treatment.
  • GRID-derived information is available on a Research Use Only basis.

O&M Backlog Reaches $130.1 M with New Contracts and Renewals as H2O Innovation Consolidates Brand

Retrieved on: 
Tuesday, August 8, 2023
Engineering, Other Energy, Utilities, Environment, Manufacturing, Green Technology, Energy, HEO, Maintenance, Drinking water, New York City Department of Environmental Protection, Hudson Valley, Innovation, L.L.C, JCO, Environmental protection, Corporation, Water, SEDAR, Environmental consulting, O&M, TSX, EC, Safety, Legislation

These projects, with a combined annual value of $4.6 M, bring the Corporation’s O&M backlog to $130.1 M, further solidifying its position in the industry.

Key Points: 
  • These projects, with a combined annual value of $4.6 M, bring the Corporation’s O&M backlog to $130.1 M, further solidifying its position in the industry.
  • H2O Innovation will provide O&M operations for the water and wastewater facilities for an initial three-year period.
  • Additional scope will be added after the first year with the hiring of a new employee.
  • Customers can expect a seamless transition as all business operations and communications now operate under the H2O Innovation name.

Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology

Retrieved on: 
Friday, June 30, 2023
Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, Registry, University Challenge 2013–14, Public, Overalls, Survival, Cohort (statistics), Risk, JCO, American Joint Committee on Cancer, Patient, CM, Melanoma, SEER, Mortality, Lymph node, NCI, Metastasis, Medical imaging, Pharmaceutical industry

Additionally, data from the study shows that testing with DecisionDx-Melanoma was associated with lower melanoma-specific and overall mortality relative to untested patients.

Key Points: 
  • Additionally, data from the study shows that testing with DecisionDx-Melanoma was associated with lower melanoma-specific and overall mortality relative to untested patients.
  • This large study of real-world, unselected, clinically tested patients who received our test as part of their ongoing melanoma care further supports these findings.
  • Key findings of the study include:
    DecisionDx-Melanoma independently risk-stratified patients according to their risk of dying from melanoma, consistent with previously published retrospective and prospective studies.
  • “We are looking forward to continuing our collaboration with the NCI SEER Program’s Registries to provide DecisionDx Melanoma data to the SEER registries as part of public health reporting to further advance research and patient care.”

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

Retrieved on: 
Tuesday, June 27, 2023
Bevacizumab, Doctor of Pharmacy, University, Obstetrics, American Journal of Clinical Oncology, Progression-free survival, Associate professor, American Society of Clinical Oncology, OS, Woman, Doctor of Philosophy, JCO, PFS, European Institute of Oncology, ASCO, Control, Journal, IRCCS, Dor, University of Milano-Bicocca, HIV disease progression rates, Risk, CORT, Death, Society, PARK, Chair, Pharmaceutical industry, MD, Gynaecology, Patient

Patients who would have met the eligibility requirements for Corcept’s confirmatory Phase 3 ROSELLA trial did especially well.

Key Points: 
  • Patients who would have met the eligibility requirements for Corcept’s confirmatory Phase 3 ROSELLA trial did especially well.
  • “The benefits experienced by patients in the intermittent dosing group are meaningful especially given the simple, oral dosing and favorable safety profile of relacorilant.
  • Our single goal is to replicate the great results seen in our phase 2 trial,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “We believe relacorilant has the potential to become a new standard of care for all patients with platinum-resistant ovarian cancer.”

Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics

Retrieved on: 
Monday, June 26, 2023
Time trial, Therapy, CCI, ESR1, Clinical trial, Cancer, Fulvestrant, Mutation, JCO Clinical Cancer Informatics, Research, JCO, Trial of the century, Eli Lilly, Tempus, Patient, IRB, Oncology, TIME, Breast cancer, Pharmaceutical industry, Nursing

The second method used the Tempus TIME Trial Network that would rapidly open the trial, at the site of care, after identifying a patient with a mutation of interest and eligibility for the trial.

Key Points: 
  • The second method used the Tempus TIME Trial Network that would rapidly open the trial, at the site of care, after identifying a patient with a mutation of interest and eligibility for the trial.
  • Sermonix was able to leverage Tempus’ network of individual clinical sites that use a pre-approved clinical trial agreement and regulatory process, as well as a central IRB.
  • The duration for full clinical trial agreement execution averaged 200.5 days for traditional sites, compared to 7.6 days for TIME Trial sites.
  • These results demonstrate the value of employing both models for biomarker-driven studies.”
    Tempus is an industry leader analyzing multimodal data to identify actionable clinical trial options for cancer patients.

JennyCo Launches The $JCO Utility Token To Power Its Web3 Healthcare Data Exchange

Retrieved on: 
Wednesday, June 14, 2023
Stargazer, Health care, MATIC, CEX, JCO, MetaMask, SAN, AI, DEX, ERC20, Cryptocurrency, Polygon, Blockchain, Uniswap

SAN DIEGO, June 14, 2023 /PRNewswire/ -- JennyCo, Inc., a first-of-its-kind healthcare data exchange powered by Web3 and AI, has announced that its utility token, $JCO, has been minted as an ERC-20 token on the Polygon (MATIC) network.

Key Points: 
  • SAN DIEGO, June 14, 2023 /PRNewswire/ -- JennyCo, Inc., a first-of-its-kind healthcare data exchange powered by Web3 and AI, has announced that its utility token, $JCO, has been minted as an ERC-20 token on the Polygon (MATIC) network.
  • The $JCO utility token is available for purchase as of June 14, 2023 at 13:00 UTC on MEXC exchange (CEX) and on Uniswap (DEX).
  • JennyCo is focused on correcting the imbalances in the healthcare data marketplace by supporting individual ownership of healthcare information with direct compensation.
  • With a personalized AI health companion, JennyCo analyzes your data and provides healthcare insights and recommendations tailored specifically to you within the app.

Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer

Retrieved on: 
Monday, May 22, 2023
Doctor of Pharmacy, Prior, ESR1, CDK, MBC, CI, Cancer, Fulvestrant, Mutation, Research, Biomarker, Chinese, Doctor of Philosophy, JCO, PFS, HR, Drug resistance, Standard of care, CTC, HIV disease progression rates, Patient, Breast cancer, Medicine, Triple-negative breast cancer, DOI, Massachusetts General Hospital, Pharmaceutical industry, Medical imaging, MD

BEVERLY, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) who progress on endocrine therapy (ET) in combination with cyclin-dependent kinase 4/6 inhibition (CDK 4/6i). The paper, titled “A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression,” was published in JCO Precision Oncology (DOI 10.1200/PO.22.00532).

Key Points: 
  • Currently, patients with HR+/HER2- metastatic breast cancer (mBC) receive endocrine therapy (ET) in combination with cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) as first line treatment.
  • Thus, there is an unmet need to develop biomarkers for response to guide treatment decisions among patients with acquired ESR1 pathogeneic mutations.
  • In the post-palbociclib setting, administration of abemaciclib resulted in a two-fold longer PFS in patients with CDKi-R(-) compared to patients with CDKi-R(+).
  • “This work represents an important step forward as we strive to develop a novel genomic and molecular biomarker to aid in therapy selection for patients with metastatic breast cancer.

BAE Systems’ APKWS® laser-guidance kits successfully tested by U.S. counter-drone office

Retrieved on: 
Tuesday, March 28, 2023
Engineering, Defense, Technology, Manufacturing, Other Technology, Drones, Other Defense, Aircraft, Exercise, Foreign, UAS, Class 2, Multimedia, M151, JCO, Yuma Proving Ground, C-UAS, Head, BAE Systems, United States Department of Defense aerospace vehicle designation, APKWS, Joint, BAE, Foreign Military Sales, Credit, Yuma

The Joint Counter-Small Unmanned Aircraft Systems Office (JCO) has successfully tested BAE Systems’ APKWS® laser-guidance kits in a counter-unmanned aircraft systems (C-UAS) mission.

Key Points: 
  • The Joint Counter-Small Unmanned Aircraft Systems Office (JCO) has successfully tested BAE Systems’ APKWS® laser-guidance kits in a counter-unmanned aircraft systems (C-UAS) mission.
  • The testing against Class-2 UAS paves the way for fielding of the precision-guided rockets to partner nations around the globe.
  • View the full release here: https://www.businesswire.com/news/home/20230328005337/en/
    APKWS® laser-guidance kits have been successfully tested against drones.
  • (Credit: BAE Systems)
    APKWS transforms unguided rockets into smart munitions for precision strikes on soft and lightly armored targets.

RAFAEL's DRONE DOME to be Tested by FAA for Use at US Airport

Retrieved on: 
Tuesday, March 7, 2023
Aircraft, Atlantic City International Airport, Federal Aviation Administration, Content as a service, National Airspace System, Research, U.S. Department of Defense Strategy for Operating in Cyberspace, C-UAS, Airport, Intelligence, Yuma Proving Ground, Algorithm, United States Department of Defense, UAS, Defense, RSGS, KACY, Yuma, Navigation, JCO, Raytheon Intelligence, Information and Services

The process will involve research, testing, and evaluations in order for the system to be properly utilized to deal with UAS threats and interference surrounding the KACY.

Key Points: 
  • The process will involve research, testing, and evaluations in order for the system to be properly utilized to deal with UAS threats and interference surrounding the KACY.
  • Testing will initially take place for several months at KACY with follow on performance validation at other airports in the United States.
  • In November 2022, the U.S. Department of Defense's (DoD) Joint Counter-small Unmanned Aircraft Systems Office (JCO) named and recommended for C-sUAS As A Service (CaaS) the DRONE DOME system.
  • DRONE DOME successfully demonstrated its C-UAS capabilities, which included accurate detection, identification and soft-kill capabilities against a variety of drone targets and is now eligible and has been recommended to compete for future CaaS contract opportunities.